Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Sign Up
Cited by 544

The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.

Modulation of the interleukin-6 signalling pathway and incidence rates of atherosclerotic events and all-cause mortality: analyses from the Canakinumab Anti-Inflammatory Thrombosis Outcomes Study (CANTOS)

Ridker, Paul M, Libby, Peter, MacFadyen, Jean G, Thuren, Tom, Ballantyne, Christie, Fonseca, Francisco, Koenig, Wolfgang, Shimokawa, Hiroaki, Everett, Brendan M, Glynn, Robert J·2018·European Heart Journal
DOI 10.1093/eurheartj/ehy310
Open this paper in CoChat — free account

Abstract

Aims Canakinumab, a monoclonal antibody targeting interleukin (IL)-1β, reduces rates of recurrent cardiovascular events without lowering lipids. It is uncertain, however, to what extent these beneficial cardiovascular outcomes are mediated through interleukin-6 (IL-6) signalling, an issue with substantial pathophysiologic consequences and therapeutic implications. Methods and results A total of 4833 stable atherosclerosis patients in the Canakinumab Anti-Inflammatory Thrombosis Outcomes Study (CANTOS) had IL-6 levels measured before randomization and after treatment with placebo or one of three doses of canakinumab (50 mg, 150 mg, or 300 mg) given subcutaneously once every 3 months. Participants were followed for up to 5 years (median follow-up 3.7 years). Compared with those allocated to placebo, CANTOS participants receiving canakinumab who achieved on-treatment IL-6 levels below the study median value of 1.65 ng/L experienced a 32% reduction in major adverse cardiovascular events [MACE, multivariable adjusted hazard ratio (HRadj) 0.68, 95% confidence interval (CI) 0.56-0.82; P Conclusion CANTOS provides proof of concept evidence in humans that modulation of the IL-6 signalling pathway, at least with canakinumab, associates with reduced cardiovascular event rates, independent of lipid lowering. Clinical trial registration ClinicalTrials.gov NCT01327846.

Overview

Integrity signals

Registry

Crossref · 10.1093/eurheartj/ehy310

Cites

6 of 6 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Research works printed but not linked: 25

  1. Ridker, 2000, Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men, Circulation, 101, 1767, 10.1161/01.CIR.101.15.1767 · DOI · Paper page
  2. Kaptoge, 2014, Inflammatory cytokines and risk of coronary heart disease: new prospective study and updated meta-analysis, Eur Heart J, 35, 578, 10.1093/eurheartj/eht367 · DOI
  3. Held, 2017, Inflammatory biomarkers, interleukin-6 and C-reactive protein and outcomes in stable coronary heart disease: experiences from the STABILITY (Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy) Trial, J Am Heart Assoc, 6, e005077., 10.1161/JAHA.116.005077 · DOI
  4. Fanola, 2017, Interleukin-6 and the risk of adverse outcomes in patients after an acute coronary syndrome: observations from the SOLID-TIMI 52 (Stabilization of Plaque Using Darapladib-Thrombolysis in Myocardial Infarction 52) trial, J Am Heart Assoc, 6, e005637., 10.1161/JAHA.117.005637 · DOI
  5. Lindmark, 2001, Relationship between interleukin 6 and mortality in patients with unstable coronary artery disease: effects of an early invasive or noninvasive strategy, JAMA, 286, 2107, 10.1001/jama.286.17.2107 · DOI
  6. Lindahl, 2000, Markers of myocardial damage and inflammation in relation to long-term mortality in unstable coronary artery disease. FRISC Study Group. Fragmin during Instability in Coronary Artery Disease, N Engl J Med, 343, 1139, 10.1056/NEJM200010193431602 · DOI
  7. Ridker, 2017, Anti-inflammatory therapy with canakinumab for atherosclerotic disease, N Engl J Med, 377, 1119, 10.1056/NEJMoa1707914 · DOI · Paper page
  8. Ridker, 2018, Relationship of C-reactive protein reduction to cardiovascular event reduction following treatment with canakinumab: a secondary analysis from the CANTOS randomized controlled trial, Lancet, 391, 319, 10.1016/S0140-6736(17)32814-3 · DOI
  9. Loppnow, 1989, Adult human vascular endothelial cells express the IL6 gene differentially in response to LPS or IL1, Cell Immunol, 122, 493, 10.1016/0008-8749(89)90095-6 · DOI
  10. Loppnow, 1990, Proliferating or interleukin-1 activated human vascular smooth muscle cells secrete copious interleukin-6, J Clin Invest, 85, 731, 10.1172/JCI114498 · DOI
  11. Ridker, 2017, Effect of interleukin-1β inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomized, double-blind, placebo-controlled trial, Lancet, 390, 1833, 10.1016/S0140-6736(17)32247-X · DOI · Paper page
  12. Daniels, 2017, Pretenders and contenders: inflammation, C-reactive protein, and interleukin-6, J Am Heart Assoc, 6, e007490, 10.1161/JAHA.117.007490 · DOI
  13. Ridker, 2016, From C-reactive protein to interleukin-6 to interleukin-1: moving upstream to identify novel targets for atheroprotection, Circ Res, 118, 145, 10.1161/CIRCRESAHA.115.306656 · DOI · Paper page
  14. Mahmud, 2005, Arterial stiffness is related to systemic inflammation in essential hypertension, Hypertension, 46, 1118, 10.1161/01.HYP.0000185463.27209.b0 · DOI
  15. Lee, 2007, Association of interleukin-6 and C-reactive protein with subclinical carotid atherosclerosis (the Rancho Bernardo Study), Am J Cardiol, 99, 99, 10.1016/j.amjcard.2006.07.070 · DOI
  16. Amar, 2006, Interleukin 6 is associated with subclinical atherosclerosis: a link with soluble intercellular adhesion molecule 1, J Hypertens, 24, 1083, 10.1097/01.hjh.0000226198.44181.0c · DOI
  17. Esteve, 2007, Serum interleukin-6 correlates with endothelial dysfunction in healthy men independently of insulin sensitivity, Diabetes Care, 30, 939, 10.2337/dc06-1793 · DOI
  18. Ridker, 2016, Residual inflammatory risk: addressing the obverse side of the atherosclerosis prevention coin, Eur Heart J, 37, 1720., 10.1093/eurheartj/ehw024 · DOI
  19. Baylis, 2017, The CANTOS trial. One important step for clinical cardiology but a giant leap for vascular biology, Arterioscler Thromb Vasc Biol, 11, e174
  20. Hansson, 2017, Inflammation and atherosclerosis. The end of a controversy, Circulation, 136, 1875, 10.1161/CIRCULATIONAHA.117.030484 · DOI
  21. Ibañez, 2017, A gigantic proof-of-concept trial, Circ Res, 121, 1320, 10.1161/CIRCRESAHA.117.312200 · DOI
  22. Weber, 2017, CANTOS trial validates the inflammatory pathogenesis of atherosclerosis. Setting the stage for a new chapter in therapeutic targeting, Circ Res, 121, 1119, 10.1161/CIRCRESAHA.117.311984 · DOI
  23. Libby, 2017, Interleukin-1 beta as a target for atherosclerosis therapy. Biological basis of CANTOS and beyond, J Am Coll Cardiol, 70, 2278, 10.1016/j.jacc.2017.09.028 · DOI
  24. Kleveland, 2016, Effect of a single dose of the interleukin-6 receptor antagonist tocilizumab on inflammation and troponin T release in patients with non-ST-elevation myocardial infarction: a double-blind, randomized, placebo-controlled phase 2 trial, Eur Heart J, 37, 2406, 10.1093/eurheartj/ehw171 · DOI
  25. Libby, 2014, Inflammation and its resolution as determinants of acute coronary syndromes, Circ Res, 114, 1867, 10.1161/CIRCRESAHA.114.302699 · DOI

Cited by

See all 544

Metadata

Authors
Ridker, P. M., Libby, P., MacFadyen, J. G., Thuren, T., Ballantyne, C., Fonseca, F., Koenig, W., Shimokawa, H., Everett, B. M., & Glynn, R. J.
Venue
European Heart Journal
Publisher
Oxford University Press (OUP)
Published
2018-08-26
Volume
39
Issue
38
Pages
3499-3507
ISSN
  • 0195-668X
  • 1522-9645
DOI
10.1093/eurheartj/ehy310
Cited by
544
References
6
Language
en
Licence
academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model (vor)
Funders
  • Novartis Pharmaceutical
  • Novartis
  • Novartis Pharmaceuticals

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review